Trial ID	Blindness or severe vision loss	End‐stage renal disease	Nonserious adverse events	Hypoglycaemic events	Health‐related quality of life	Time to progression to T2DM	Measures of blood glucose control	Socioeconomic effects
Alfawaz 2018	NI	NI	NI	NI	NI	NI	Fasting blood glucose IO	NI
PREVENT‐DM 2017	NI	NI	Adverse events SO	NI	NI	NI	HbA1c; fasting plasma glucose IO	NI
Zeng 2013	NR	NR	NR	NR	NR	NR	Fasting plasma glucose, 2‐hour plasma glucose; Quote:" At the end, OGTT was used to judge the number of cases of NGT, IGR and DM. Biochemical detection was conducted by Olympus automatic biochemical instrument, glucose detection by glucose oxidase method, and insulin detection by radioimmunoassay." (no details) IO	NR
Zhao 2013	NR	NR	Damage of liver, kidney function	NR	NR	NR	Fasting blood glucose, 2‐hour plasma glucose ND IO	NR
Iqbal Hydrie 2012	NI	NI	NI	NI	NI	NI	NI	NI
Liao 2012	NR	NR	NR	NR	NR	NR	Fasting plasma glucose, 2‐hour plasma glucose; Quote:"At the initial visit, fasting 10‐12h overnight, venous blood was taken and plasma glucose (i.e., FPG and 2hPG) was measured after OGTT (75g glucose). The above examination was repeated every 3 months. Blood glucose was measured by hexokinase method (the biochemical instrument was automatic erab‐xl‐600)." (no more detail) IO	NR
Ji 2011	NR	NR	NR	NR	NR	NR	Fasting plasma glucose, HbA1c, 2‐hour plasma glucose Quote:"All cases were followed for 2 years, outpatient follow‐up once every 2 months, patients with glucose oxidase method is used to determination of FPG, 2h postprandial blood glucose (2 HPG), treatment before and after the treatment, test weight, height, and calculate the BMI, waist circumference, hip circumference, waist‐to‐hip ratio calculation, the determination of FPG, FINS application of chemiluminescence analysis, application of biochemical analyzer determination of TC, TG, LDL cholesterol (LDL ‐ C), immune turbidimetric method is used to test the hs CRP, glycosylated hemoglobin (HbA1c) levels, Meanwhile, ISI =1/ (determined value of FINS ×FPG) was calculated. Review OGTT at the end of treatment to determine if diabetes has developed." IO	NR
Lu 2010	NR	NR	Harmful and unexpected reactions of a drug under normal usage or dosage to prevent, diagnose, treat, or regulate physiological functions	NR	NR	NR	Fasting plasma glucose; 2‐hour plasma glucose; HbA1c Quote:"Venous blood was collected 8‐12 hours after fasting, and serum was isolated for determination of blood glucose, total cholesterol, triglyceride HDL and LDL. Blood at finger tips was used to determine glycosylated hemoglobin (DS). 5 glycosylated hemoglobin analyzer).", Quote:"Oral glucose tolerance test. On the morning of fasting venous blood sampling, 300ml sugar water containing 75g glucose was drunk within 5 minutes, and blood glucose was measured by venous blood sampling 2 hours later." IO	NR
BIGPRO1 2009	NI	NI	NI	NI	NI	NI	2‐hour plasma glucose; fasting plasma glucose IO	NI
Chen 2009	NR	NR	NR	NR	NR	NR	Fasting plasma glucose, 2‐hour plasma glucose; ND IO	NR
Jin 2009	NR	NR	NR	NR	NR	NR	Fasting plasma glucose, 2‐hour plasma glucose; ND Quote:"Blood glucose was detected by tetokinase method" IO	NR
Li 2009	NR	NR	NR	NR	NR	NR	Fasting plasma glucose, 2‐hour plasma glucose; ND IO	NR
Wang 2009	NR	NR	ND	NR	NR	NR	Fasting blood glucose, 2‐hour plasma glucose; ND IO	NR
IDPP‐1 2006	NI	NI	NI	Hypoglycaemia SO, IO	NI	NI	2‐hour plasma glucose; fasting plasma glucose IO	NI
Maji 2005	NI	NI	NI	NI	NI	NI	2‐hour plasma glucose; HbA1c; fasting plasma glucose IO	NI
Fang 2004	NR	NR	NR	NR	NR	NR	Fasting plasma glucose; 2‐hour plasma glucose; ND IO	NR
DPP/DPPOS 2002	NI	NI	NI	NI	36‐Item Short‐ Form (SF‐36) health survey SO	NI	2‐hour plasma glucose; HbA1c; Fasting plasma glucose IO	"The direct costs of medical care received outside the study and indirect costs were determined annually from patient self‐report. Direct non‐medical costs were assessed once during DPP and once during DPPOS, and costs were annualized. All costs were adjusted to 2000 or 2010 U.S. dollars using the Consumer Price Index and the Medical Consumer Price Index." IO
Lu 2002	NR	NR	NR	NR	NR	NR	Fasting blood glucose, 1h plasma glucose, 2‐hour plasma glucose ND IO	NR
Li 1999	NI	NI	NI	NI	NI	NI	2‐hour plasma glucose; HbA1c; fasting plasma glucose IO	NI
Papoz 1978	NI	NI	NI	NI	NI	NI	Fasting blood glucose, 2‐hour glucose levels IO	NI
aIn addition to definition of endpoint measurement, description who measured the outcome (AO: adjudicated outcome measurement; IO: investigator‐assessed outcome measurement; SO: self‐reported outcome measurement) BMI: body mass index; CRP: C‐reactive protein; FINS: fasting insulin; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; ISI: insulin sensitivity index; ND: not defined;NI: not investigated; NR: not reported; OGTT: oral glucose tolerance test.